Compare EIG & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EIG | ARQT |
|---|---|---|
| Founded | 2000 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 980.0M | 3.3B |
| IPO Year | 2006 | 2020 |
| Metric | EIG | ARQT |
|---|---|---|
| Price | $40.44 | $21.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $34.00 |
| AVG Volume (30 Days) | 217.5K | ★ 1.2M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.15% | N/A |
| EPS Growth | N/A | ★ 88.79 |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $858,700,000.00 | $376,072,000.00 |
| Revenue This Year | N/A | $34.46 |
| Revenue Next Year | $1.76 | $29.77 |
| P/E Ratio | $88.37 | ★ N/A |
| Revenue Growth | N/A | ★ 91.34 |
| 52 Week Low | $35.73 | $11.86 |
| 52 Week High | $49.98 | $31.77 |
| Indicator | EIG | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 49.54 | 34.37 |
| Support Level | $38.14 | $19.60 |
| Resistance Level | $42.57 | $21.84 |
| Average True Range (ATR) | 0.72 | 0.88 |
| MACD | 0.23 | -0.05 |
| Stochastic Oscillator | 81.78 | 1.79 |
Employers Holdings Inc is a provider of workers' compensation insurance and services focused on small and mid-sized businesses engaged in low-to-medium hazard industries. Its customers are employers, and the insurance premiums that those employers pay to account for company revenue. Substantially all of the remaining revenue is generated through investments. The company operates exclusively in the United States, and it generates more than half of its business in California. By industry, the company has exposure to restaurants, which account for roughly a fourth of the total premiums the company earns. It operates as a single reportable segment, Insurance Operations, through its wholly owned subsidiaries.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.